Article
Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
The Tokai journal of experimental and clinical medicine - 20 Sept 2020
Kutsuzawa Naokata, Takahashi Fuminari, Tomomatsu Katsuyoshi, Obayashi Shohei, Takeuchi Tomoe, Takihara Takahisa, Hayama Naoki, Oguma Tsuyoshi, Aoki Takuya, Asano Koichiro
Abstract excerpt
Mutations in the gene encoding epidermal growth factor receptor (EGFR) are the most frequent driver mutations in lung adenocarcinoma in Japan. Exon 19 deletion and L858R mutation in exon 21 are the most common EGFR mutations. Uncommon mutations, such as G719X, S768I, and L861Q, and compound mutations, combinations of 2 common or uncommon mutations, have also been reported. EGFR tyrosine kinase inhibitors (TKIs)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.